Related Experiment Video
Updated: May 29, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Statins and intracerebral hemorrhage: a retrospective cohort study
Daniel G Hackam1, Peter C Austin, Anjie Huang
1Stroke Prevention and Atherosclerosis Research Centre, Siebens Drake Research Bldg, Room 100K, 1400 Western Rd, London, ON N6G 2V2, Canada. dhackam@uwo.ca
Insights
Statins, used after ischemic stroke, were not linked to an increased risk of intracerebral hemorrhage (ICH). This population-based study found no association between statin use and ICH in older adults.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Previous research suggested statins might increase intracerebral hemorrhage (ICH) risk.
- This concern arose from a post hoc analysis in patients with cerebrovascular disease.
Purpose of the Study:
- To investigate the association between statin therapy and ICH risk.
- Focus on patients with recent ischemic stroke in a population-based setting.
Main Methods:
- Retrospective, propensity-matched cohort study in Ontario, Canada.
- Included 17,872 patients aged 66+ initiating statins post-ischemic stroke.
- Followed for a median of 4.2 years, assessing ICH via validated coding.
Main Results:
- No significant association was found between statin use and ICH (HR=0.87; 95% CI, 0.65-1.17).
- Subgroup and dose-response analyses confirmed these findings.
- Specificity tests ruled out healthy user bias and differences in care quality.
Conclusions:
- Statin exposure following ischemic stroke is not associated with an increased risk of intracerebral hemorrhage.
- Findings suggest statins are safe regarding ICH in this patient population.
Background:
A recent post hoc analysis of a large randomized trial in patients with cerebrovascular disease suggested that statins may increase the risk of intracerebral hemorrhage (ICH).
Objective:
To examine the association between statins and ICH in patients with recent ischemic stroke in a population-based setting.
Design:
Retrospective propensity-matched cohort study with accrual from July 1, 1994, to March 31, 2008.
Setting:
Ontario, Canada.
Participants:
A total of 17 872 patients aged 66 years and older who initiated statin therapy following acute ischemic stroke and were followed for a median of 4.2 years (interquartile range, 2.4-5.0 years). To enhance causal inference, we conducted several tests of specificity to exclude healthy user bias in this sample. Main Outcome Measure Hospitalization or emergency department visit for ICH defined using validated diagnosis coding.
Results:
Overall, 213 episodes of ICH occurred. In the primary analysis comparing statin users with nonusers, we found no association between statins and ICH (hazard ratio = 0.87; 95% confidence interval, 0.65-1.17). Subgroup and dose-response analyses yielded similar results. In tests of specificity, statin therapy was not associated with bone mineral density testing, vitamin D or B(12) screening, gastrointestinal endoscopy, or elective knee arthroplasty, suggesting that results were not due to healthy user bias or differences in quality of care.
Conclusion:
Statin exposure following ischemic stroke was not associated with ICH.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
